Molecular Point-of-Care (mPOC) Global Market Analysis and Future Potential: Market Sizing, Forecasting, Trend Mapping and Competitive Analysis [Yahoo! Finance]
Danaher Corporation (DHR)
Last danaher corporation earnings: 1/30 06:00 am
Check Earnings Report
US:NYSE Investor Relations:
investors.danaher.com
Company Research
Source: Yahoo! Finance
Molecular point-of-care (mPOC) diagnostic solutions offer enhanced sensitivity and specificity compared to existing near-patient and rapid tests. They expand diagnostic capabilities in critical care units, physician offices, outpatient clinics, and community health posts, aiming to assess conditions or admit patients accurately. The concept blends the accessibility of point-of-care (POC) testing with the precision of molecular technology. The Market and Future Potential for Molecular Point-of-Care (mPOC), 11th Edition, is a valuable resource for understanding the size and growth potential of the molecular POC market from 2023-2028. mPOC has transitioned from a novel trend to a significant contributor to the market. Instruments from companies like Abbott, BioMerieux, Cepheid, and others play a substantial role in the IVD point-of-care market. Understanding these markets is crucial for assessing the opportunity in point-of-care testing and microbiology IVD. The report provides mark
Show less
Read more
Impact Snapshot
Event Time:
DHR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DHR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DHR alerts
High impacting Danaher Corporation news events
Weekly update
A roundup of the hottest topics
DHR
News
- Anti-Mullerian Hormone Test Market Projected to Reach $586.48 million by 2030 - Exclusive Report by 360iResearch [Yahoo! Finance]Yahoo! Finance
- Oligonucleotide Synthesis Market Worth $19.7 billion | MarketsandMarkets™ [Yahoo! Finance]Yahoo! Finance
- The Zacks Analyst Blog Highlights Danaher, Regeneron Pharmaceuticals, Palo Alto Networks, Workday and American Electric Power [Yahoo! Finance]Yahoo! Finance
- Top Stock Reports for Danaher, Regeneron Pharmaceuticals & Palo Alto Networks [Yahoo! Finance]Yahoo! Finance
- Danaher Co. (NYSE: DHR) had its price target raised by analysts at Citigroup Inc. from $280.00 to $290.00. They now have a "buy" rating on the stock.MarketBeat
DHR
Earnings
- 4/23/24 - Beat
DHR
Sec Filings
- 4/26/24 - Form 4
- 4/25/24 - Form 4
- 4/25/24 - Form 4
- DHR's page on the SEC website